Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung
暂无分享,去创建一个
Gaetano Rocco | Natalia Malara | Virginia Tirino | Giuseppe Viglietto | Gennaro Chiappetta | G. Viglietto | R. Franco | R. Savino | G. Chiappetta | C. de Marco | G. Rocco | G. Pirozzi | V. Tirino | N. Malara | Renato Franco | Fernanda Fabiani | D. Malanga | Carmela De Marco | Donatella Malanga | Marianna Scrima | Giuseppe Pirozzi | Nicola De Rosa | Silvia de Gisi | Rocco Savino | F. Fabiani | M. Scrima | Silvia de Gisi | N. De Rosa
[1] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[2] E. Gabrielson. Worldwide trends in lung cancer pathology , 2006, Respirology.
[3] Spyro Mousses,et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.
[4] G. Viglietto,et al. Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. , 2005, The American journal of pathology.
[5] Andrew D. Yates,et al. Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.
[6] J. Testa,et al. Perturbations of the AKT signaling pathway in human cancer , 2005, Oncogene.
[7] O. Razorenova,et al. Akt1 in Endothelial Cell and Angiogenesis , 2006, Cell cycle.
[8] Ming-Sound Tsao,et al. K-ras mutations in non-small-cell lung carcinoma: a review. , 2006, Clinical lung cancer.
[9] M. Meyerson,et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. , 2002, Cancer research.
[10] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[11] Tak W. Mak,et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.
[12] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[13] A. Toker,et al. Akt/PKB Signaling in Cancer: A Function in Cell Motility and Invasion , 2006, Cell cycle.
[14] Alfonso Bellacosa,et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer , 2002, Nature Medicine.
[15] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[16] R. Guo,et al. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. , 2006, Lung cancer.
[17] W. Park,et al. Somatic mutations of the ERBB4 kinase domain in human cancers , 2006, International journal of cancer.
[18] J. Minna,et al. Focus on lung cancer. , 2002, Cancer cell.
[19] G. Viglietto,et al. Akt-Dependent T198 Phosphorylation of Cyclin-Dependent Kinase Inhibitor p27kip1 in Breast Cancer , 2004, Cell cycle.
[20] H. Sasaki,et al. PIK3CA mutation status in Japanese lung cancer patients. , 2006, Lung cancer.
[21] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[22] Li Mao,et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.